| 发明名称 |
Modified antigens |
| 摘要 |
Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis. |
| 申请公布号 |
US9200044(B2) |
申请公布日期 |
2015.12.01 |
| 申请号 |
US201414557929 |
申请日期 |
2014.12.02 |
| 申请人 |
GlaxoSmithKline Biologicals, S.A. |
发明人 |
Blais Normand;Gelinas Anne-Marie;Brown James;Murphy Dennis;Mettens Pascal |
| 分类号 |
A61K39/04;C07K14/35 |
主分类号 |
A61K39/04 |
| 代理机构 |
|
代理人 |
Kron Eric J. |
| 主权项 |
1. A polynucleotide comprising a nucleic acid sequence encoding a modified mycobacterium Rv3616c protein, said modified mycobacterium Rv3616c protein comprising a first polypeptide and a second polypeptide, the first polypeptide being located towards the N-terminus relative to the second polypeptide, and wherein:
(i) the first polypeptide has at least 98% identity to residues 1-134 of SEQ ID No: 1; and (ii) the second polypeptide has at least 98% identity to residues 155-392 of SEQ ID No: 1; wherein the first and second polypeptides are (A) directly linked or (B) indirectly linked via a third polypeptide having at least 80% identity to a sequence corresponding to residues 135-154 in SEQ ID No:1 in which a contiguous portion of at least 3 amino acids has been deleted. |
| 地址 |
Rixensart BE |
